Table 3.
PFS/ORR by HRD sub-group with rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 part 1)5
| HRD subgroups of high-grade ovarian cancer | Number of patients in each group | Median PFS, months (95% CI) | Hazard ratio | ORR
|
|
|---|---|---|---|---|---|
| RECIST, % (n, 95% CI) | RECIST/CA125, % (n, 95% CI) | ||||
| BRCA mutant | 40 | 12.8 (9.0–14.7) | 0.27, P<0.0001 | 80% (32, 64–91) | 85% (34, 70–94) |
| BRCA wild type and LOH high | 82 | 5.7 (5.3–7.6) | 0.62, P<0.011 | 29% (24, 20–40) | 44% (34, 33–55) |
| BRCA wild type and LOH low | 70 | 5.2 (3.6–5.5) | – | 10% (7, 4–20) | 20% (14, 11–31) |
Abbreviations: BRCA, breast and ovarian cancer susceptibility gene; CI, confidence interval; CA125, cancer antigen 125; HRD, homologous recombination repair deficiency; LOH, loss of heterozygosity; ORR, objective response rate; PFS, progression-free survival; RECIST, Response Evaluation Criteria In Solid Tumors (Version 1.1).